Skip to content

Republish This Story

* Please read before republishing *

We’re happy to make this story available to republish for free under an Attribution-NonCommercial-NoDerivatives Creative Commons license as long as you follow our republishing guidelines, which require that you credit The 19th and retain our pixel. See our full guidelines for more information.

To republish, simply copy the HTML at right, which includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to The 19th. Have questions? Please email [email protected].

— The Editors

Loading...

Modal Gallery

/

Menu

  • Our Mission
  • Our Team
  • Latest Stories
  • Upcoming Events
  • Contact Us
  • Newsletter
  • Donate
  • Work With Us
  • Fellowships
    • From the Collection

      Changing Child Care

      Illustration of a woman feeding a baby a bottle
      • As climate change worsens hurricane season in Louisiana, doulas are ensuring parents can safely feed their babies

        Jessica Kutz · May 5
      • Supreme Court Justice Samuel Alito argued abortion isn’t an economic issue. But is that true?

        Chabeli Carrazana · May 4
      • Pregnant people are at 'greater risk' in states hit hard by wildfire smoke, air pollution, new report shows

        Jessica Kutz · April 20
    • From the Collection

      Next-Gen GOP

      Illustration of a woman riding an elephant
      • Mayra Flores’ victory set a record for women in Congress. It also reflects the growing visibility of Republican Latinas

        Candice Norwood · June 21
      • A banner year for Republican women

        Amanda Becker · November 11
      • Republican women could double representation in the U.S. House

        Amanda Becker · November 4
    • From the Collection

      On The Rise

      Illustration of three women marching
      • Biden’s new environmental justice office aims to tackle the health impacts disproportionately faced by people of color

        Jessica Kutz · June 2
      • Jessica Cisneros takes on the last anti-abortion U.S. House Democrat

        Amanda Becker · February 25
      • Meet J. Michelle Childs, South Carolina judge and possible Supreme Court contender

        Candice Norwood · February 18
    • From the Collection

      Pandemic Within a Pandemic

      Illustration of four people marching for Black Lives Matter with coronavirus as the backdrop
      • Some LGBTQ+ people worry that the COVID-19 vaccine will affect HIV medication. It won’t.

        Orion Rummler · November 23
      • Why are more men dying from COVID? It’s a complicated story of nature vs. nurture, researchers say

        Mariel Padilla · September 22
      • Few incarcerated women were released during COVID. The ones who remain have struggled.

        Candice Norwood · August 17
    • From the Collection

      Portraits of a Pandemic

      Illustration of a woman wearing a mask and holding up the coronavirus
      • For family caregivers, COVID is a mental health crisis in the making

        Shefali Luthra · October 8
      • A new database tracks COVID-19’s effects on sex and gender

        Shefali Luthra · September 15
      • Pregnant in a pandemic: The 'perfect storm for a crisis'

        Shefali Luthra · August 25
    • From the Collection

      The 19th Explains

      People walking from many articles to one article where they can get the context they need on an issue.
      • The 19th Explains: How pregnant people can prepare for a summer of heat waves

        Jessica Kutz · June 17
      • The 19th Explains: How new Title IX guidelines on sexual misconduct may give more help to survivors

        Nadra Nittle · June 14
      • The 19th Explains: How would overturning Roe v. Wade affect IVF?

        Jennifer Gerson · May 27
    • From the Collection

      The Electability Myth

      Illustration of three women speaking at podiums
      • Mayra Flores’ victory set a record for women in Congress. It also reflects the growing visibility of Republican Latinas

        Candice Norwood · June 21
      • Stepping in after tragedy: How political wives became widow lawmakers

        Mariel Padilla · May 24
      • Do term limits help women candidates? New York could be a new testing ground

        Barbara Rodriguez · January 11
    • From the Collection

      The Impact of Aging

      A number of older people walking down a path of information.
      • 'I'm planning on working until the day I die': Older women voters are worried about the future

        Mariel Padilla · June 3
      • Climate change is forcing care workers to act as first responders

        Jessica Kutz · May 31
      • Woman alleges that an assisted living facility denied her admission because she is transgender

        Sara Luterman · November 8
    • From the Collection

      Voting Rights

      A series of hands reaching for ballots.
      • Florida’s redistricting fight continues. The head of the state League of Women Voters talks about what’s at stake.

        Barbara Rodriguez · April 19
      • Women have been sounding the alarm ahead of Texas’ first-in-the-nation primary

        Barbara Rodriguez · February 28
      • LGBTQ+ people of color are at risk from rising voter restrictions as federal protections falter in the Senate, advocates say

        Orion Rummler · January 19

    View all collections

  • Explore by Topic

    • Abortion
    • Business & Economy
    • Caregiving
    • Coronavirus
    • Education
    • Election 2020
    • Elections 2022
    • Environment & Climate
    • Health
    • Immigration
    • Inside The 19th
    • Justice
    • LGBTQ+
    • Politics
    • Race
    • Sports
    • Technology

    View All Topics

Home
  • Our Mission
  • Our Team
  • Latest Stories
  • Upcoming Events
  • Contact Us
  • Newsletter
  • Donate
  • Work With Us
  • Fellowships

We’re an independent, nonprofit newsroom reporting on gender, politics and policy. Read our story.

Support The 19th

As a nonprofit newsroom, members are critical to our sustainability. Your financial support helps make our journalism possible.

Become a Member

Donate to support our mission

The 19th thanks our sponsors. Become one.

A photo of a dose of the Johnson & Johnson vaccine and syringe.
The Johnson & Johnson vaccine is the only vaccine among leading candidates given as a single dose. (Photo by Michael Ciaglo/Getty Images)

Coronavirus

For women workers, new COVID vaccine candidates could alleviate access challenges

Johnson & Johnson's one-shot vaccine is 85 percent effective against severe illness, and could be far easier to deploy.

Shefali Luthra

Health Reporter

Shefali Luthra portrait

Published

2021-01-29 14:42
2:42
January 29, 2021
pm

Share

  • Twitter
  • Facebook
  • Email

Two COVID-19 vaccine candidates could help alleviate the challenges in vaccinating women — particularly frontline workers — that have emerged in the nation’s quest for herd immunity.

Data posted by Novavax and Johnson & Johnson suggests their COVID-19 vaccines could offer strong protection against the virus. But both candidates appeared far less effective against a new variant of the virus that has spread through South Africa and appeared in South Carolina Thursday. The emergence of the highly potent B.1351 variant has only furthered the need for speedy vaccinations.

Novavax is still some time away from bringing an immunization to the United States. The company’s data, posted Thursday, came from an early analysis of its large-scale clinical trial, which hasn’t concluded. Its efficacy dropped from 90 percent in the United Kingdom-based trial to 49 percent in South Africa, where it predominantly addressed B.1351. The vaccine requires two doses.

The 19th thanks our sponsors. Become one.

The Johnson & Johnson vaccine candidate, the company said, showed 85 percent efficacy against severe illness, and 66 percent efficacy against moderate to severe illness. Those results come after a completed clinical trial, and could have a much quicker impact.

“This has important potential and real implications, both domestically and globally,” said Anthony Fauci, the nation’s top infectious disease expert, who runs the National Institute of Allergy and Infectious Diseases, at a White House briefing.

Johnson & Johnson shared the information via press release, and has not yet posted the full data from its clinical trial, including information about side effects. But the company said it intends to apply for emergency use authorization — the same designation that has allowed the distribution of Moderna’s and Pfizer’s vaccines — as early as next week. If authorization is granted, that could bring new doses into distribution sometime in February. The company has said it expects to supply 100 million doses of the vaccine to the United States by the end of June, though a large amount likely won’t be available until April.

A newsletter you can relate to

Storytelling that represents you, delivered to your inbox.

You have been subscribed!

Submitting…

Uh-oh! Something went wrong. Please try again later.

For that vaccine, protection against the virus varies based on the coronavirus variant. In Johnson & Johnson’s U.S.-based trial, the vaccine showed 72 percent efficacy against moderate to severe illness. In South Africa, where it predominantly encountered B.1351, efficacy dropped to 57 percent. But even in South Africa, the vaccine appears highly effective in preventing severe illness. No deaths were reported amongst trial participants who took the vaccine.

Unlike the Moderna and Pfizer vaccines, Johnson & Johnson’s product consists of only one injection, and can be stored in a regular refrigerator rather than hyper-cold freezer storage. Those differences could make it far easier to distribute the vaccine through places like local doctors’ offices, community pharmacies, schools, pop-up clinics and community health centers. It could also be easier to provide via massive distribution sites, such as sports stadiums. 

Those are places that may not necessarily have deep-freezer capacity, but can be easier to access for someone facing transportation or child care barriers that make it hard to travel many miles for a vaccine. Those are issues that disproportionately affect women, and especially working women.

“The [lack of] cold-chain requirements will help access a lot. And it’s effective — 85 percent is good. This will get more people vaccinated,” said Rupali Limaye, an associate scientist at Johns Hopkins University. 

The one-shot requirement could be critical in reaching women who aren’t regularly connected to the health care system, who are nervous about sharing personal paperwork with local health officials, or who don’t have paid time off to go get two separate vaccine doses.

One question health authorities are grappling with is if they should target a Johnson & Johnson vaccine — that is somewhat less effective, but requires only one dose — toward lower-income neighborhoods. There, they would reach people more likely to run the risk of coronavirus exposure, but also who may not be able to access a pharmacy with advanced freezer technology. And more people are likely to face economic barriers when it comes to getting two vaccine doses. 

“Do you prioritize Johnson & Johnson to go to communities where there’s a high risk of contracting severe COVID, because you know more people have access?” Limaye said. “On the flip side, wouldn’t you want to send Pfizer and Moderna, but to be effective you need more doses? Is that feasible? It’s definitely complicated.”

Still, it’s not yet fully clear what role new Johnson & Johnson vaccines would play in the national coronavirus response. Combined with existing orders of Pfizer and Moderna vaccines, the 100 million doses from Johnson & Johnson could be enough to vaccinate the vast majority of the adult population. 

But the Biden administration has also announced efforts to procure 200 million more vaccine doses from Pfizer and Moderna — enough to potentially vaccinate the adult population even without Johnson & Johnson. That purchase hasn’t yet been finalized, though, and it would still take until the end of summer to vaccinate everyone, the administration has said. 

White House Press Secretary Jennifer Psaki declined to comment on how the introduction of Johnson & Johnson doses could affect its vaccination plan, saying that the administration did not want to speculate on something that wasn’t yet authorized for use. 

“No matter what happens with other approvals, we will have the supply to vaccinate the entire nation,” said Andy Slavitt, a senior adviser to the White House COVID-19 Response, in a Friday briefing.

Share

  • Twitter
  • Facebook
  • Email

Support The 19th

As a nonprofit newsroom, members are critical to our sustainability. Your financial support helps make our journalism possible.

Become a Member

Donate to support our mission

Up Next

Two geriatric nurses walk through a corridor in the Pauline Krone Home for the Elderly of the Tübingen elderly care centre with protective equipment that they have put on to carry out rapid antigen-corona tests. (

Coronavirus

Most nursing homes say they won’t be able to stay open another year due to pandemic costs

Increased staffing, personal protective equipment and testing contributed to the mounting financial crisis that could jeopardize the care of thousands of older Americans, many of whom are women.

Read the Story

The 19th
The 19th is a 501(c)(3) tax-exempt organization. Our stories are free to republish in accordance with these guidelines.

  • Donate
  • Subscribe to the Newsletter
  • Attend an Event
  • Jobs
  • Fellowships
  • Contact Us
  • About Us
  • Community Guidelines
  • Membership
  • Membership FAQ
  • Major Gifts
  • Sponsorship
  • Privacy
  • Twitter
  • Facebook
  • Instagram